No | Age | Gender | Duration (month) | MSA | MAA | CDASI | ILD | Oesophageal lesions | Assessment of muscular diseases | |||
Muscle VAS | Serum CK (IU/L) | MMT8 score | Muscle pathological score | |||||||||
1 | 66 | Female | 6 | Anti-SAE | – | 35 | + | – | 4 | 520 | 70 | 4 |
2 | 46 | Female | 2 | Anti-TIFγ | – | 42 | + | 5 | 300 | 68 | 5 | |
3 | 66 | Male | 2 | Anti-MDA5 | RO52 | 28 | + | – | 4. | 879 | 68 | 4 |
4 | 18 | Female | 3 | Anti-Mi2 | – | 21 | + | -- | 9 | 18 322 | 46 | 9 |
5 | 38 | Male | 2 | Anti-MDA5 | RO52 | 35 | – | – | 3 | 220 | 72 | 3 |
6 | 57 | Female | 2 | Anti-MDA5 | RO52 | 28 | + | – | 7 | 529 | 59 | 7 |
7 | 54 | Female | 3 | Anti-SAE | – | 49 | + | – | 6 | 3239 | 64 | 6 |
8 | 41 | Female | 4 | Anti-Jo1 | – | 14 | + | – | 1 | 3132 | 78 | 1 |
9 | 52 | Female | 3 | Anti-NXP2 | – | 42 | – | + | 8 | 5279 | 42 | 8 |
10 | 38 | Female | 7 | Anti-TIFγ | RO52 | 48 | – | – | 3 | 100 | 72 | 3 |
11 | 41 | Male | 8 | Anti-MDA5 | RO52 | 56 | + | – | 2 | 302 | 75 | 2 |
12 | 34 | Female | 6 | Anti-TIFγ | – | 49 | – | – | 3 | 378 | 74 | 3 |
13 | 48 | Female | 2 | – | – | 42 | + | + | 2 | 150 | 76 | 2 |
14 | 71 | Female | 8 | – | – | 21 | + | – | 1 | 311 | 78 | 1 |
15 | 34 | Female | 2 | Anti-NXP2 | – | 35 | – | – | 4 | 805 | 70 | 4 |
16 | 35 | Male | 4 | Anti-TIFγ | – | 58 | – | + | 2 | 229 | 72 | 2 |
–, negative; CDASI, Cutaneous Dermatomyositis Disease Area and Severity Index; CK, creatine kinase; DM, dermatomyositis; ILD, interstitial lung disease; MAA, myositis-associated antibodies; MMT8, manual muscle test; MSA, myositis-specific antibodies; VAS, Visual Analogue Scale.